Developer docs
API playgroundTry for free, no card

Search company profiles

BerGenBio

Full company profile

uuid0002qf9

Namestring
BerGenBio
Legal namestring
BerGenBio, AS.
Websiteurl
bergenbio.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

BerGenBio was a Norwegian clinical-stage biopharmaceutical company founded in 2007 and listed on the Oslo Stock Exchange under ticker BGBIO. Its original therapeutic focus was first-in-class selective AXL kinase inhibitors targeting treatment-resistant aggressive cancers. On October 29, 2025, BerGenBio completed a merger with Oncoinvent ASA, financed by an oversubscribed NOK 130 million rights issue; the combined entity was renamed Oncoinvent ASA and trades under ticker ONCIN on Oslo Børs. The legacy AXL program remains part of the portfolio, but the merged company's strategic center of gravity has shifted to Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery with a single targeted dose at a recommended 7MBq level.

Radspherin is being developed primarily for peritoneal metastases from ovarian cancer (currently in a multi-country Phase 2 trial with 54 of a planned ~108 patients enrolled across 10 sites in the US, Spain, Norway, Belgium, UK, and Italy) and is also being evaluated in a Phase 1/2a trial in colorectal cancer. The technology platform rests on a proprietary size-controlled calcium carbonate microparticle carrier, protected by a composition-of-matter patent valid until 2035 (2036 in some jurisdictions) and a new CNIPA-granted patent extending coverage in China to 2041. Positive final Phase 1 data in ovarian cancer with 24-month follow-up were presented at the ESGO 2026 Congress, and no dose-limiting toxicity has been observed at the recommended dose.

The company is pre-revenue with no commercialized products, deriving no recurring license or product revenue today. Its go-to-market, once Radspherin is approved, is planned to run through hospital pharmacies and specialized oncology treatment centers. Marketing activity to date has been limited to investor relations, healthcare conference participation (DNB Nordic, H.C. Wainwright, Arctic Securities, Carnegie), and peer-reviewed publications in journals such as Gynecologic Oncology, Journal of Surgical Oncology, and Frontiers in Medicine. Leadership post-merger comprises CEO Øystein Soug, CFO Dr Ramzi Amri, and Chair Gillies O'Bryan-Tear, supported by a full board and audit, remuneration, and nomination committees. The company is headquartered at Gullhaugveien 7, 0484 Oslo, Norway.

Short descriptiontext

BerGenBio, merged into Oncoinvent ASA in October 2025, is a Norwegian clinical-stage biotech developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery, with lead programs in peritoneal metastases from ovarian and colorectal cancers.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBergen, Norway
HQ citystring
Bergen
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AXL kinase inhibitors, radiopharmaceutical therapy, clinical-stage oncology, alpha-emitting therapeutics, cancer biopharmaceutical
Industry2 codes
1Oncology Specialty Pharmaceuticals
CodeHLAIACAAPrimaryYes
2Medical Oncology
CodeHLAKAFABPrimaryNo
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Oncology Therapeutics
Social media profiles1 record
Revenue model1 record
1Pre-commercial / Product Revenue (Future)
TypeOne Time License
Description

BerGenBio was a clinical-stage biotech company. The merger with Oncoinvent combined pipelines to develop Radspherin® for abdominal cavity cancer treatment. No commercial revenue currently as products are in clinical trials.

morningstar.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BerGenBio ASA is a clinical-stage biopharmaceutical company developing selective AXL kinase inhibitors and other targeted oncology therapeutics for aggressive cancers, including non-small cell lung cancer and COVID-19. Following its October 2025 merger with Oncoinvent ASA, the combined entity (renamed Oncoinvent ASA) is focused on advancing Radspherin®, an alpha-emitting radiopharmaceutical therapy designed to eradicate residual cancer cells in the abdominal cavity after surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • No dose-limiting toxicity observed at recommended dose of 7MBq
+1 more record
Product overview1 text field

BerGenBio was a biotech company developing first-in-class AXL inhibitors for aggressive diseases, including treatment-resistant cancers. Following the merger with Oncoinvent ASA completed on October 29, 2025, the combined entity was renamed Oncoinvent ASA. The merged company's lead product is Radspherin, a receptor-independent alpha radiopharmaceutical for eradicating cancer cells in the abdominal cavity after surgery with a single targeted dose. The product portfolio includes Radspherin for abdominal cavity cancer treatment (ovarian and colorectal cancers) and the legacy AXL inhibitor program from BerGenBio.

Product and service3 records
1Radspherin®
CategoryRadiopharmaceutical Therapy
Description

Alpha-emitting radiopharmaceutical therapy administered as a single targeted dose designed to eradicate cancer cells in the abdominal cavity after surgery. Developed by Oncoinvent and now the lead clinical asset of the merged company, targeting peritoneal metastases from cancers such as ovarian and colorectal.

2Bemcentinib
CategorySmall-Molecule Oncology Drug
Description

Selective AXL kinase inhibitor developed by BerGenBio and evaluated in Phase 2 clinical trials, including as a first-line treatment in combination with pembrolizumab and chemotherapy in non-squamous non-small cell lung cancer (NSCLC) patients, and in COVID-19 studies.

3Tilvestamab
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Oncoinvent ASA
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-30
Description

BerGenBio announced merger agreement to acquire Oncoinvent ASA, a Norwegian biotech company developing Radspherin® for abdominal cavity cancer treatment. The combined entity planned a fully underwritten rights issue. Merger completed October 29, 2025, with combined entity renamed to Oncoinvent ASA.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BerGenBio

Clinical-Stage Oncology Therapeuticsbergenbio.com

BerGenBio, merged into Oncoinvent ASA in October 2025, is a Norwegian clinical-stage biotech developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery, with lead programs in peritoneal metastases from ovarian and colorectal cancers.

What BerGenBio does

BerGenBio was a Norwegian clinical-stage biopharmaceutical company founded in 2007 and listed on the Oslo Stock Exchange under ticker BGBIO. Its original therapeutic focus was first-in-class selective AXL kinase inhibitors targeting treatment-resistant aggressive cancers. On October 29, 2025, BerGenBio completed a merger with Oncoinvent ASA, financed by an oversubscribed NOK 130 million rights issue; the combined entity was renamed Oncoinvent ASA and trades under ticker ONCIN on Oslo Børs. The legacy AXL program remains part of the portfolio, but the merged company's strategic center of gravity has shifted to Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery with a single targeted dose at a recommended 7MBq level.

Radspherin is being developed primarily for peritoneal metastases from ovarian cancer (currently in a multi-country Phase 2 trial with 54 of a planned ~108 patients enrolled across 10 sites in the US, Spain, Norway, Belgium, UK, and Italy) and is also being evaluated in a Phase 1/2a trial in colorectal cancer. The technology platform rests on a proprietary size-controlled calcium carbonate microparticle carrier, protected by a composition-of-matter patent valid until 2035 (2036 in some jurisdictions) and a new CNIPA-granted patent extending coverage in China to 2041. Positive final Phase 1 data in ovarian cancer with 24-month follow-up were presented at the ESGO 2026 Congress, and no dose-limiting toxicity has been observed at the recommended dose.

The company is pre-revenue with no commercialized products, deriving no recurring license or product revenue today. Its go-to-market, once Radspherin is approved, is planned to run through hospital pharmacies and specialized oncology treatment centers. Marketing activity to date has been limited to investor relations, healthcare conference participation (DNB Nordic, H.C. Wainwright, Arctic Securities, Carnegie), and peer-reviewed publications in journals such as Gynecologic Oncology, Journal of Surgical Oncology, and Frontiers in Medicine. Leadership post-merger comprises CEO Øystein Soug, CFO Dr Ramzi Amri, and Chair Gillies O'Bryan-Tear, supported by a full board and audit, remuneration, and nomination committees. The company is headquartered at Gullhaugveien 7, 0484 Oslo, Norway.

BerGenBio firmographics

Firmographics
Name
BerGenBio
Legal name
BerGenBio, AS.
Website
https://bergenbio.com
Company type
Public
Founded year
2007
Operating status
Acquired
Headcount range
11–50 employees
Short description
BerGenBio, merged into Oncoinvent ASA in October 2025, is a Norwegian clinical-stage biotech developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical designed to eradicate residual cancer cells in the abdominal cavity after surgery, with lead programs in peritoneal metastases from ovarian and colorectal cancers.
Ownership category
akta.pro rank

BerGenBio industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Oncology Specialty Pharmaceuticals (HLAIACAA)
akta.pro secondary industry
Medical Oncology (HLAKAFAB)

Keywords

  • AXL kinase inhibitors
  • Radiopharmaceutical therapy
  • Clinical-stage oncology
  • Alpha-emitting therapeutics
  • Cancer biopharmaceutical

Where BerGenBio is headquartered

Location

Headquarters

HQ city
Bergen
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

BerGenBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-commercial / Product Revenue (Future): BerGenBio was a clinical-stage biotech company. The merger with Oncoinvent combined pipelines to develop Radspherin® for abdominal cavity cancer treatment. No commercial revenue currently as products are in clinical trials.

Distribution channels1 record

Marketing channels3 records

BerGenBio product offering

Product offering

Core offering

BerGenBio ASA is a clinical-stage biopharmaceutical company developing selective AXL kinase inhibitors and other targeted oncology therapeutics for aggressive cancers, including non-small cell lung cancer and COVID-19. Following its October 2025 merger with Oncoinvent ASA, the combined entity (renamed Oncoinvent ASA) is focused on advancing Radspherin®, an alpha-emitting radiopharmaceutical therapy designed to eradicate residual cancer cells in the abdominal cavity after surgery.

Product overview

BerGenBio was a biotech company developing first-in-class AXL inhibitors for aggressive diseases, including treatment-resistant cancers. Following the merger with Oncoinvent ASA completed on October 29, 2025, the combined entity was renamed Oncoinvent ASA. The merged company's lead product is Radspherin, a receptor-independent alpha radiopharmaceutical for eradicating cancer cells in the abdominal cavity after surgery with a single targeted dose. The product portfolio includes Radspherin for abdominal cavity cancer treatment (ovarian and colorectal cancers) and the legacy AXL inhibitor program from BerGenBio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Radspherin® Alpha-emitting radiopharmaceutical therapy administered as a single targeted dose designed to eradicate cancer cells in the abdominal cavity after surgery. Developed by Oncoinvent and now the lead clinical asset of the merged company, targeting peritoneal metastases from cancers such as ovarian and colorectal.
  • Bemcentinib Selective AXL kinase inhibitor developed by BerGenBio and evaluated in Phase 2 clinical trials, including as a first-line treatment in combination with pembrolizumab and chemotherapy in non-squamous non-small cell lung cancer (NSCLC) patients, and in COVID-19 studies.
  • Tilvestamab

Quantifiable outcome

  • No dose-limiting toxicity observed at recommended dose of 7MBq
  • +1 more outcomes

Companies that use BerGenBio

Customer profile

Segments2 records

Ideal customer profiles2 records

BerGenBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BerGenBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Oncoinvent ASAflagshipStrategic or Co-development Partner · 30 June 2025BerGenBio announced merger agreement to acquire Oncoinvent ASA, a Norwegian biotech company developing Radspherin® for abdominal cavity cancer treatment. The combined entity planned a fully underwritten rights issue. Merger completed October 29, 2025, with combined entity renamed to Oncoinvent ASA.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

BerGenBio competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

BerGenBio social profiles

Digital presence

BerGenBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BerGenBio leadership team

Management profile

Number of profiles

Profiles14 records

BerGenBio funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BerGenBio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BerGenBio

What does BerGenBio do?

BerGenBio ASA is a clinical-stage biopharmaceutical company developing selective AXL kinase inhibitors and other targeted oncology therapeutics for aggressive cancers, including non-small cell lung cancer and COVID-19. Following its October 2025 merger with Oncoinvent ASA, the combined entity (renamed Oncoinvent ASA) is focused on advancing Radspherin®, an alpha-emitting radiopharmaceutical therapy designed to eradicate residual cancer cells in the abdominal cavity after surgery.

Is BerGenBio a public or private company?

BerGenBio is a public company. It is classified as public and is currently acquired.

When was BerGenBio founded?

BerGenBio was founded in 2007. It employs 11 to 50 people.

Where is BerGenBio based?

BerGenBio is headquartered in Bergen, Norway, in the Europe region.

How does BerGenBio make money?

One revenue line is on record: pre-commercial / Product Revenue (Future).

Does BerGenBio have an API?

No public API is recorded for BerGenBio.

What industry is BerGenBio in?

BerGenBio's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmafiaThe Best Startup Ecosystems in Norway: Bergen — the blue economy specialistBergen is Norway's most sector-specialized startup city, with clusters in seafood, media technology, and marine science. It has 26 funded companies raising $301M, but faces thin venture depth and a center-of-gravity drift. The article advises founders to target sector-specific clusters and raise externally.news.cision.comMerger of BerGenBio and Oncoinvent completedThe merger between BerGenBio ASA and Oncoinvent ASA has been completed and registered with the Norwegian Register of Business Enterprises, with BerGenBio renamed Oncoinvent ASA and the original Oncoinvent dissolved. The combined company issued 117,554,012 merger consideration shares to former Oncoinvent shareholders, resulting in a new share capital of NOK 156,641,128. The combined entity plans to provide an update on the ongoing Phase 2 ovarian cancer study and financial status in a virtual presentation on November 4, 2025.news.cision.comMerger of BerGenBio and Oncoinvent completedThe statutory triangular merger between BerGenBio ASA and Oncoinvent ASA was completed on October 29, 2025, after registration with the Norwegian Register of Business Enterprises, with Oncoinvent being dissolved and BerGenBio renamed to Oncoinvent ASA. The Combined Company issued 117,554,012 merger consideration shares to former Oncoinvent shareholders, establishing a new share capital of NOK 156,641,128 divided into 156,641,128 shares. The Combined Company will provide a status update on the merger along with a quarterly update, including progress on an ongoing Phase 2 ovarian cancer study, during a live virtual presentation scheduled for November 4, 2025.news.cision.comBerGenBio and Oncoinvent – Last day of trading in the shares of OncoinventBerGenBio ASA and Oncoinvent ASA announced that October 29, 2025 is the last day of trading in Oncoinvent shares on Euronext Growth Oslo, completing their statutory triangular merger. The merger follows approval of the prospectus and previous announcements on October 24 and 28, 2025. Oncoinvent is a clinical-stage biotechnology company developing Radspherin®, a radiopharmaceutical therapy for cancer, with ongoing Phase 2 trials in the US, UK, and Europe.news.cision.comBerGenBio ASA: Approval and publication of prospectusThe Financial Supervisory Authority of Norway approved a prospectus prepared by BerGenBio ASA on 28 October 2025 in connection with its statutory triangular merger with Oncoinvent ASA and a fully underwritten rights issue to raise gross proceeds of NOK 130 million. The prospectus covers the listing of 117,554,012 new Merger Shares on the Oslo Stock Exchange, along with 43 to 764 million Offer Shares in the Rights Issue. Trading in the Merger Shares is expected to commence on or about 30 October 2025, with the subscription period for the Rights Issue expected to run from 17 November to 1 December 2025.TradingViewBerGenBio ASA: Approval and publication of prospectusThe Financial Supervisory Authority of Norway approved a prospectus prepared by BerGenBio ASA for the statutory triangular merger with Oncoinvent ASA and an associated fully underwritten rights issue. The prospectus covers 117,554,012 new merger shares and offer shares for a rights issue to raise gross proceeds of NOK 130 million in the combined company. Trading in the merger shares on the Oslo Stock Exchange is expected to commence on or about 30 October 2025, with the subscription period for the rights issue expected to commence on 17 November 2025.news.cision.comBerGenBio and Oncoinvent – Key Dates for Completion of MergerBerGenBio ASA and Oncoinvent ASA announced the key dates for completion of their statutory triangular merger, with completion expected on 29 October 2025 and first day of trading in the combined company on 30 October 2025. Oncoinvent shareholders will receive 1.202680493545220 BerGenBio shares per Oncoinvent share held, with a total of 117,554,012 consideration shares to be issued. Following the merger, BerGenBio will change its company name to "Oncoinvent ASA" and continue its listing on the Oslo Stock Exchange under the ticker "ONCIN".PR NewswireBerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issueBerGenBio ASA and Oncoinvent ASA have entered into a merger agreement, with BerGenBio as the acquiring entity in a statutory merger, followed by a fully underwritten rights issue of NOK 130 million. The exchange ratio allocates 25% to BerGenBio shareholders and 75% to Oncoinvent shareholders, valuing BerGenBio at NOK 65 million (19% premium) and Oncoinvent at NOK 195.5 million (8% premium), with the combined company expected to be renamed Oncoinvent and potentially uplisted to Euronext Oslo Børs. The merger, backed by major shareholders including Meteva AS, Hadean Ventures, and Linc AB, will fund Oncoinvent's clinical development of Radspherin® and extend cash runway into 2027, with completion expected around mid-September 2025 pending shareholder and regulatory approvals.PR NewswireBerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issueBerGenBio ASA and Oncoinvent ASA have announced a proposed merger, with BerGenBio as the acquiring entity, structured at a 25%/75% exchange ratio valuing BerGenBio at NOK 65 million (19% premium) and Oncoinvent at NOK 195.5 million (8% premium). Following the merger, the combined company will conduct a fully underwritten rights issue of NOK 130 million to fund Oncoinvent's clinical development, providing cash runway into 2027 beyond the Phase 2 trial readout expected in H2 2026. The merged entity, expected to be renamed Oncoinvent, aims to advance Radspherin® for treating peritoneal carcinomatosis and ovarian cancer.PR NewswireAnnouncement of fully underwritten rights issueBerGenBio ASA announced a fully underwritten rights issue to raise approximately NOK 130 million, subject to and subsequent to the completion of its merger with Oncoinvent ASA (expected mid-September 2025), with the rights issue to be implemented in October 2025. The proceeds will fund clinical development milestones for Oncoinvent's Radspherin® cancer treatment including Phase 1 final data, Phase 2 recruitment completion, and interim Phase 2 data, as well as provide general corporate cash runway into 2027. The rights issue is fully underwritten by a consortium including Oncoinvent's largest shareholders and external investors, with the subscription price to be set at approximately 35% discount to market price.